VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag
Portfolio Pulse from
Verastem's New Drug Application (NDA) for avutometinib, aimed at treating recurrent KRAS mutant ovarian cancer, has been accepted by the FDA for priority review. This news has led to a 41% increase in Verastem's stock price.
January 02, 2025 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Verastem's NDA for avutometinib has been accepted by the FDA for priority review, leading to a significant 41% increase in its stock price.
The FDA's acceptance of Verastem's NDA for priority review is a significant regulatory milestone, indicating potential accelerated approval. This positive development has directly led to a substantial increase in Verastem's stock price, reflecting investor optimism about the drug's market potential.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100